Baricitinib Oral Tablet

DRUG4 trials

Sponsors

Hospital Universitario de Fuenlabrada, Azienda Ospedaliero, Universitaria Pisana, Pirogov Russian National Research Medical University, South Valley University

Conditions

Alopecia AreataCOVID-19COVID-19 PneumoniaCovid-19Mild to ModerateSARS PneumoniaSARS-CoV 2

Phase 1

Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

Active, not recruitingNCT06545110

South Valley UniversityAlopecia Areata

Start: 2023-09-01End: 2024-10-30Target: 120Updated: 2024-08-09

Phase 2

Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

Hospital Universitario de FuenlabradaCOVID-19 Pneumonia

Start: 2020-05-07End: 2021-09-30Updated: 2021-08-03

Baricitinib Compared to Standard Therapy in Patients With COVID-19

Azienda Ospedaliero, Universitaria PisanaCovid-19, SARS-CoV 2, SARS Pneumonia

Start: 2020-05-20End: 2020-07-30Target: 126Updated: 2020-05-20

Unknown Phase

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

CompletedNCT05302947

Pirogov Russian National Research Medical UniversityCOVID-19, Mild to Moderate

Start: 2020-02-01End: 2021-06-30Updated: 2022-04-08

Related Papers

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.

2021-06-1887 citations